Home
Start with a quick read
Ask a question above, set filters, or open one of these.
Landscape
Assets by most advanced phase
Each drug or biologic counted once, at the highest phase it reaches in this search.
Asset pipeline
Sorted by most advanced phase, then active trials. Includes comparators and combination partners that appear as interventions. Click a sponsor for its profile.
Expected primary completions by quarter
Open trials (recruiting, active or not yet recruiting) over the next two years, by phase. Dates are the sponsor's current estimate.
Upcoming readouts
Soonest first. Primary completion is when the last participant is assessed for the main outcome; top-line data usually follows within months.
Sponsor mix
Trials by type of lead sponsor.
Sponsor league table
Lead sponsors with subsidiaries rolled up. Click a row for the sponsor profile.
Randomization
Interventional trials.
Blinding
Interventional trials, by masking.
Why trials stop
Terminated, withdrawn and suspended trials, grouped by the sponsor's stated reason.
Attrition by phase
Share of closed trials that ended early (terminated, withdrawn or suspended).
Top sponsors by phase
Lead sponsor, with subsidiaries rolled up (e.g. Genentech → Roche). Click a sponsor for its profile.
Trial starts per year
By study start date (actual or anticipated).
Most-studied interventions
Drugs and biologics, dose text and placebo removed.
Phase × status
Trial counts.
Enrollment and duration by phase
Enrollment uses actual counts where reported, otherwise planned. Duration is start → primary completion, completed trials with actual dates only.
Median enrollment by phase
Participants per trial.
Median duration by phase
Months, start → primary completion.
Trials by country
A trial counts once per country it runs in.
US trials by state
A trial counts once per state.
Most active sites
Facilities ranked by number of trials in this search. Facility names are free text, so some variants may remain.